Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ates Mailing address

<< Previous

Bullboard Posts

Next >>

Comment by Muddyorkon Aug 01, 2021 7:12pm

155 Views

Post# 33638863

RE:RE:RE:RE:RE:RE:Ates Mailing address

"I asked Dan about the picture ( I emailed him the picture...it is the smaller building on the right" Stupid me right? Verbatim buddy. I dont have a problem with your regular enthusiasm and attention seeking ",im leaving until the stock is this much" posts but come on dude. I do appreciate your excitement for this company but let the big boys do their job (good or bad) depends who you ask i guess...

<< Previous

Bullboard Posts

Next >>

Why Roth Capital Partners gives GameSquare a 'buy' rating